Company news
CRISPR Therapeutics AG news in 2021
CRISPR Therapeutics AG's news releases, calls and decks from 2021, newest first.
CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell malignancies
November 21, 2021
CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes
November 15, 2021
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results
November 2, 2021
CRISPR Therapeutics Reports Positive Results from its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell malignancies
October 11, 2021
CRISPR Therapeutics to Host Virtual Event Highlighting CTX110™ Clinical Data
October 4, 2021
CRISPR Therapeutics to Present Preclinical Data at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
September 30, 2021
CRISPR Therapeutics to Participate in the Chardan’s 5th Annual Genetic Medicines Conference
September 27, 2021
CRISPR Therapeutics to Participate in the Canaccord Genuity 41st Annual Growth Conference
August 4, 2021
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2021 Financial Results
July 28, 2021
CRISPR Therapeutics and Capsida Biotherapeutics Announce Strategic Collaboration to Develop Gene-Edited Therapies for Amyotrophic Lateral Sclerosis and Friedreich’s Ataxia
June 14, 2021
Vertex and CRISPR Therapeutics Present New Data in 22 Patients With Greater Than 3 Months Follow-Up Post-Treatment With Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at European Hematology Association Annual Meeting
June 10, 2021
Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual Congress
May 11, 2021
CRISPR Therapeutics and Nkarta Announce Global Collaboration to Develop Gene-Edited Cell Therapies for Cancer
May 5, 2021
CRISPR Therapeutics Announces Trials in Progress Poster Presentation at the 2021 American Society of Clinical Oncology Annual Meeting
April 27, 2021
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results
April 26, 2021
Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia
April 19, 2021
CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel Approach to Increasing CAR-T Cell Function
April 9, 2021
CRISPR Therapeutics to Participate in the 20th Annual Needham Virtual Healthcare Conference
April 5, 2021
CRISPR Therapeutics Announces Poster Presentation at the American Association for Cancer Research 2021 Annual Meeting
March 9, 2021
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
February 15, 2021
CRISPR Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Oncology Day
February 4, 2021
CRISPR Therapeutics Announces the Appointment of Philippe Drouet as Chief Commercial Officer
January 31, 2021
Decks in 2021
- Technical Presentation (October 2021)
Technical · 20 slides · Oct 12, 2021
- Investor Presentation (2021)
Investor deck · 35 slides · 2021